MeSH term
Frequency | Condition_Probility | Adult | 47 | 0.0 |
Aged | 45 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
DNA, Viral/analysis | 2 | 0.0 |
Gene Amplification | 16 | 2.0 |
Heterozygote | 6 | 0.0 |
Humans | 374 | 0.0 |
Middle Aged | 58 | 0.0 |
Polymerase Chain Reaction | 21 | 0.0 |
Research Support, Non-U.S. Gov't | 279 | 0.0 |
Biopsy | 2 | 0.0 |
English Abstract | 11 | 0.0 |
Multigene Family | 3 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 3 | 1.0 |
Tumor Cells, Cultured | 56 | 0.0 |
Vimentin/genetics | 2 | 20.0 |
Binding Sites | 24 | 0.0 |
Blotting, Western | 12 | 0.0 |
Cells, Cultured | 18 | 0.0 |
DNA/genetics/metabolism | 6 | 1.0 |
*DNA-Binding Proteins | 11 | 0.0 |
Electrophoretic Mobility Shift Assay | 3 | 0.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Molecular Sequence Data | 96 | 0.0 |
Mutation | 29 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Protein Binding | 14 | 0.0 |
Aged, 80 and over | 18 | 0.0 |
Apoptosis/*genetics | 4 | 1.0 |
Case-Control Studies | 3 | 0.0 |
Cyclin-Dependent Kinases/genetics | 2 | 3.0 |
DNA, Neoplasm/analysis | 7 | 0.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
Female | 100 | 0.0 |
Male | 62 | 0.0 |
Neoplasm Proteins/genetics | 4 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
*Proto-Oncogene Proteins | 6 | 0.0 |
*Saccharomyces cerevisiae Proteins | 7 | 0.0 |
Transcription Factors/genetics | 8 | 0.0 |
Acute Disease | 7 | 0.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
DNA-Binding Proteins/genetics/physiology | 2 | 2.0 |
*Gene Expression Profiling | 4 | 0.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
Leukemia, Myeloid/*genetics | 4 | 2.0 |
Oncogene Proteins/genetics | 2 | 2.0 |
RNA/metabolism | 2 | 0.0 |
Translocation, Genetic | 14 | 1.0 |
Animals | 150 | 0.0 |
Apoptosis | 9 | 0.0 |
Cell Division | 24 | 0.0 |
Cell Line | 68 | 0.0 |
*Cell Transformation, Neoplastic | 20 | 4.0 |
Gene Expression | 23 | 0.0 |
Mice | 86 | 0.0 |
Mice, Nude | 11 | 0.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 17 | 17.0 |
Rats | 31 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 134 | 0.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/metabolism | 3 | 2.0 |
Glycogen Synthase Kinases | 2 | 3.0 |
*Gene Expression Regulation | 21 | 1.0 |
Promoter Regions (Genetics) | 23 | 0.0 |
Proto-Oncogene Proteins c-myc/chemistry/*physiology | 3 | 75.0 |
Structure-Activity Relationship | 7 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Down-Regulation | 6 | 0.0 |
Gene Expression Regulation, Neoplastic | 16 | 0.0 |
*Genes, myc | 62 | 29.0 |
Histone Deacetylases/*physiology | 2 | 18.0 |
Homeostasis | 2 | 0.0 |
Neuroblastoma/*genetics | 2 | 2.0 |
Repressor Proteins/*physiology | 4 | 3.0 |
*Gene Expression Regulation, Neoplastic | 14 | 0.0 |
Genes, myc/*genetics | 17 | 18.0 |
In Situ Hybridization, Fluorescence | 20 | 0.0 |
*Nucleoside-Diphosphate Kinase | 2 | 3.0 |
RNA, Messenger/genetics/metabolism | 9 | 0.0 |
Transcription Factors/*genetics | 10 | 0.0 |
*Chromosome Aberrations | 8 | 1.0 |
Chromosome Painting | 2 | 4.0 |
Gene Amplification/*genetics | 6 | 5.0 |
Genes, myc | 34 | 12.0 |
*In Situ Hybridization, Fluorescence | 2 | 1.0 |
Leukemia, Myelocytic, Acute/*genetics | 3 | 2.0 |
Myelodysplastic Syndromes/*genetics | 3 | 4.0 |
Chromosome Aberrations | 9 | 1.0 |
Chromosome Deletion | 4 | 0.0 |
Chromosomes, Human, Pair 8/genetics | 6 | 6.0 |
Diagnosis, Differential | 2 | 0.0 |
Genes, p53 | 9 | 1.0 |
Genotype | 4 | 0.0 |
Phenotype | 11 | 0.0 |
Base Sequence | 81 | 0.0 |
Chick Embryo | 5 | 0.0 |
Dimerization | 4 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Fluorescence | 2 | 0.0 |
Protein Binding/drug effects | 4 | 1.0 |
Proto-Oncogene Proteins c-myc/*antagonists & inhibitors/metabolism | 2 | 66.0 |
*Transcription Factors | 25 | 1.0 |
Cell Cycle | 7 | 0.0 |
Chromatin/metabolism | 3 | 1.0 |
Models, Biological | 9 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/*metabolism/*physiology | 2 | 66.0 |
Transcription, Genetic | 30 | 0.0 |
Burkitt Lymphoma/*genetics/pathology | 3 | 75.0 |
Centromere/genetics | 2 | 2.0 |
Chromosome Mapping | 18 | 0.0 |
Enhancer Elements (Genetics) | 4 | 1.0 |
Genes, Immunoglobulin/*genetics | 2 | 4.0 |
Apoptosis/*physiology | 5 | 0.0 |
*Cell Cycle Proteins | 6 | 0.0 |
Epidermis/metabolism | 2 | 5.0 |
Fibroblasts/cytology | 2 | 0.0 |
Mice, Transgenic | 14 | 0.0 |
S Phase | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
p14ARF Protein/*metabolism | 3 | 17.0 |
Apoptosis/physiology | 2 | 0.0 |
Cell Transformation, Neoplastic | 16 | 2.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Proteasome Endopeptidase Complex | 3 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
Immunoenzyme Techniques | 2 | 0.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
Adolescent | 8 | 0.0 |
Chromosome Banding | 6 | 0.0 |
Comparative Study | 35 | 0.0 |
Gene Dosage | 9 | 2.0 |
Gene Rearrangement/genetics | 2 | 4.0 |
Lymphoma, B-Cell/*genetics | 4 | 5.0 |
Lymphoma, Large-Cell, Diffuse/*genetics | 2 | 8.0 |
Mutation/genetics | 4 | 0.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Transcription Factors/biosynthesis/genetics | 2 | 2.0 |
Cell Cycle Proteins/genetics | 2 | 2.0 |
Flow Cytometry | 12 | 0.0 |
Genes, Tumor Suppressor | 11 | 1.0 |
Immunohistochemistry | 18 | 0.0 |
Oncogenes/genetics | 3 | 4.0 |
Neoplasm Metastasis | 3 | 0.0 |
Oncogenes/*genetics | 5 | 6.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Cell Division/drug effects | 6 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
Gene Expression Regulation/drug effects | 8 | 0.0 |
Mice, Inbred C3H | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/genetics/*metabolism | 13 | 29.0 |
Receptors, Estrogen/genetics | 4 | 6.0 |
Recombinant Fusion Proteins/genetics/metabolism | 6 | 0.0 |
Cell Transformation, Neoplastic/*pathology | 3 | 11.0 |
Cytogenetic Analysis | 2 | 1.0 |
Disease Progression | 8 | 0.0 |
Immunophenotyping | 5 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Breast Neoplasms/*genetics | 8 | 1.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Models, Genetic | 6 | 0.0 |
*Mutation | 10 | 0.0 |
*Gene Amplification | 24 | 6.0 |
Enzyme Activation | 6 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
*Muscle Proteins | 4 | 1.0 |
Phosphorylation | 15 | 0.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
*Repressor Proteins | 17 | 1.0 |
Signal Transduction | 14 | 0.0 |
Breast Neoplasms/*genetics/pathology | 6 | 2.0 |
In Situ Hybridization, Fluorescence/*methods | 3 | 3.0 |
Proto-Oncogene Proteins c-myc/*genetics | 9 | 21.0 |
Survival Analysis | 4 | 0.0 |
Binding, Competitive | 5 | 0.0 |
Cell Line, Transformed | 4 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 7 | 0.0 |
Hamsters | 4 | 0.0 |
Promoter Regions (Genetics)/genetics | 6 | 0.0 |
Response Elements/genetics | 2 | 1.0 |
Telomerase/genetics/*metabolism | 2 | 8.0 |
Trans-Activation (Genetics) | 12 | 0.0 |
Transfection | 43 | 0.0 |
Acetylation | 3 | 0.0 |
Cyclins/*genetics | 2 | 1.0 |
DNA-Binding Proteins/physiology | 4 | 1.0 |
HL-60 Cells | 10 | 1.0 |
Histones/metabolism | 4 | 1.0 |
Promoter Regions (Genetics)/*physiology | 2 | 2.0 |
Proto-Oncogene Proteins c-myc/*physiology | 13 | 34.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Breast Neoplasms/*genetics/*pathology | 2 | 3.0 |
*CDC2-CDC28 Kinases | 2 | 0.0 |
Cell Cycle/drug effects/*physiology | 2 | 4.0 |
Estradiol/pharmacology | 2 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Amino Acid Sequence | 52 | 0.0 |
Gene Deletion | 9 | 0.0 |
Peptide Fragments/genetics/metabolism | 2 | 1.0 |
Virus Replication | 3 | 0.0 |
DNA Primers | 10 | 0.0 |
Loss of Heterozygosity | 4 | 0.0 |
Time Factors | 12 | 0.0 |
3T3 Cells | 14 | 0.0 |
Fibroblasts/metabolism | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 12 | 0.0 |
Telomerase/*metabolism | 2 | 4.0 |
*Transcription, Genetic | 17 | 0.0 |
Up-Regulation | 5 | 0.0 |
Binding Sites/genetics | 3 | 0.0 |
Proto-Oncogene Proteins c-myc/genetics/metabolism | 3 | 10.0 |
*Trans-Activation (Genetics) | 3 | 0.0 |
Brain Neoplasms/*genetics | 4 | 2.0 |
Glioblastoma/*genetics | 2 | 2.0 |
Oligonucleotide Array Sequence Analysis | 9 | 0.0 |
*Oncogenes | 35 | 8.0 |
Cell Differentiation | 12 | 0.0 |
Cell Transformation, Neoplastic/genetics | 5 | 1.0 |
Mice, Knockout | 4 | 0.0 |
Neoplasm Proteins/physiology | 2 | 3.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
Protein Structure, Tertiary | 7 | 0.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
Colonic Neoplasms/*genetics | 2 | 2.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 2 | 1.0 |
Introns | 7 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
*Trans-Activators | 2 | 0.0 |
Transcription Factors/biosynthesis/*genetics | 3 | 2.0 |
Child | 8 | 0.0 |
Child, Preschool | 5 | 0.0 |
Infant | 3 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Neoplasm Staging | 10 | 0.0 |
Prognosis | 13 | 0.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
Cell Cycle/*physiology | 3 | 1.0 |
*Genes, erbB-2 | 4 | 4.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Reference Values | 3 | 0.0 |
Telomerase/metabolism | 2 | 3.0 |
COS Cells | 5 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Cercopithecus aethiops | 8 | 0.0 |
Response Elements | 2 | 0.0 |
Trans-Activation (Genetics)/*physiology | 3 | 2.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Cell Differentiation/physiology | 3 | 0.0 |
Proto-Oncogene Proteins/*physiology | 4 | 1.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Carcinoma, Small Cell/genetics/pathology | 2 | 22.0 |
*Genes, p53 | 6 | 1.0 |
Lung Neoplasms/*genetics/pathology | 4 | 4.0 |
Lymphatic Metastasis | 6 | 0.0 |
Genes, erbB-2 | 7 | 8.0 |
Sex Factors | 2 | 0.0 |
*Apoptosis | 3 | 0.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Protein p53/metabolism | 4 | 0.0 |
Ubiquitins/metabolism | 2 | 1.0 |
Genes, ras | 9 | 3.0 |
Mutagenesis | 6 | 0.0 |
Ornithine Decarboxylase/genetics | 2 | 16.0 |
Proteins/genetics | 5 | 0.0 |
Proto-Oncogene Proteins/*genetics | 19 | 1.0 |
Burkitt Lymphoma/*genetics | 8 | 27.0 |
Chromosomes, Human, Pair 14/genetics | 2 | 2.0 |
Exons/genetics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Immunoglobulins, Heavy-Chain/genetics | 6 | 3.0 |
RNA, Messenger/genetics | 14 | 0.0 |
Transcription, Genetic/genetics | 3 | 0.0 |
*Translocation, Genetic | 18 | 2.0 |
Cloning, Molecular | 23 | 0.0 |
Genes, Reporter | 7 | 0.0 |
Luciferases/genetics | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Restriction Mapping | 10 | 0.0 |
Sequence Homology, Nucleic Acid | 9 | 0.0 |
Transcription Factors/metabolism | 6 | 0.0 |
Cell Division/physiology | 6 | 0.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Proto-Oncogenes | 7 | 3.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
Gene Expression/physiology | 2 | 0.0 |
Genes, myc/genetics | 5 | 6.0 |
In Vitro | 4 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
*Trisomy | 3 | 2.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
Oncogenes | 8 | 3.0 |
*Protein Biosynthesis | 4 | 0.0 |
Protein p16 | 3 | 2.0 |
Proto-Oncogene Proteins/genetics | 11 | 2.0 |
p14ARF Protein | 2 | 2.0 |
Cyclin D1/genetics | 4 | 6.0 |
Genes, Retinoblastoma | 4 | 4.0 |
Blotting, Northern | 14 | 0.0 |
Blotting, Southern | 16 | 0.0 |
DNA-Binding Proteins/*metabolism | 8 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/biosynthesis/genetics/*metabolism | 2 | 100.0 |
Tetradecanoylphorbol Acetate/pharmacology | 6 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
DNA, Neoplasm/genetics | 12 | 1.0 |
Disease-Free Survival | 5 | 0.0 |
Multivariate Analysis | 5 | 0.0 |
Immunoblotting | 5 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Proto-Oncogene Proteins c-myc/metabolism | 3 | 3.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
*Carrier Proteins | 3 | 0.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Gene Expression Regulation | 26 | 0.0 |
Hela Cells | 15 | 0.0 |
Proteins/*genetics | 4 | 0.0 |
Transcription Factors/*physiology | 5 | 1.0 |
DNA/metabolism | 7 | 0.0 |
Regulatory Sequences, Nucleic Acid | 9 | 1.0 |
BRCA2 Protein | 3 | 0.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
Linkage (Genetics) | 2 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Fibroblasts | 7 | 1.0 |
*Nuclear Proteins | 5 | 0.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Tetracycline/pharmacology | 3 | 3.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
Ultraviolet Rays | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/biosynthesis | 5 | 15.0 |
*Proto-Oncogenes | 27 | 4.0 |
*Nucleic Acid Hybridization | 4 | 7.0 |
Chimeric Proteins | 2 | 2.0 |
Cell Division/genetics | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Genes, bcl-2 | 2 | 1.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Neoplasm Transplantation | 5 | 0.0 |
Tamoxifen/analogs & derivatives/pharmacology | 2 | 7.0 |
Cell Transformation, Neoplastic/*genetics | 4 | 2.0 |
DNA Replication/genetics | 2 | 3.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Risk Factors | 2 | 0.0 |
Half-Life | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Alternative Splicing | 2 | 0.0 |
DNA, Neoplasm/*genetics | 6 | 2.0 |
Nucleic Acid Hybridization | 16 | 1.0 |
Transplantation, Heterologous | 7 | 0.0 |
Point Mutation | 5 | 0.0 |
*Neoplasm Proteins | 4 | 0.0 |
Plasmids | 10 | 0.0 |
Cell Hypoxia | 2 | 1.0 |
G1 Phase | 3 | 0.0 |
Melanoma/chemistry/pathology/*radiotherapy | 2 | 100.0 |
Protein p53/*analysis | 2 | 1.0 |
Proto-Oncogene Proteins c-myc/*analysis | 4 | 30.0 |
Proto-Oncogene Proteins c-raf/*analysis | 2 | 100.0 |
*Radiation Tolerance | 2 | 3.0 |
ras Proteins/*analysis | 2 | 33.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Stomach/chemistry/pathology | 2 | 66.0 |
Stomach Neoplasms/*chemistry/mortality/pathology | 2 | 20.0 |
Survival Rate | 4 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Proto-Oncogene Proteins c-myc/*genetics/metabolism | 4 | 33.0 |
Biological Transport | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Dogs | 2 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Xenopus laevis | 2 | 0.0 |
DNA-Binding Proteins/*genetics | 11 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Conserved Sequence | 3 | 0.0 |
*E-Box Elements | 2 | 33.0 |
Lymphocytes | 2 | 1.0 |
Precipitin Tests | 7 | 0.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Breast Neoplasms/*genetics/metabolism | 2 | 1.0 |
*Gene Expression | 3 | 0.0 |
RNA, Messenger/analysis | 7 | 0.0 |
*Cell Division | 3 | 1.0 |
Repressor Proteins/physiology | 2 | 5.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 14 | 0.0 |
Sequence Deletion | 7 | 0.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
*Helix-Loop-Helix Motifs | 4 | 4.0 |
*Leucine Zippers | 2 | 4.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
In Situ Hybridization | 9 | 0.0 |
Immunoglobulins, Heavy-Chain/*genetics | 5 | 3.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/*biosynthesis | 2 | 11.0 |
U937 Cells | 2 | 0.0 |
Clone Cells | 3 | 0.0 |
Karyotyping | 12 | 0.0 |
Neoplasms/genetics | 3 | 2.0 |
Helix-Loop-Helix Motifs | 7 | 2.0 |
Proto-Oncogene Proteins c-jun/*metabolism | 2 | 2.0 |
Bone Marrow Transplantation | 2 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Consensus Sequence | 6 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Sequence Alignment | 6 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Apoptosis/genetics/*physiology | 2 | 5.0 |
Lymphoma/*genetics | 3 | 6.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
Translocation, Genetic/*genetics | 4 | 1.0 |
DNA Mutational Analysis | 4 | 0.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 3.0 |
Life Tables | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 2 | 1.0 |
Remission Induction | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Vero Cells | 3 | 1.0 |
Chromosomes, Human, Pair 8 | 7 | 5.0 |
Cyclin-Dependent Kinases/*genetics | 2 | 3.0 |
DNA-Binding Proteins/*chemistry | 2 | 2.0 |
Genetic Vectors | 6 | 0.0 |
Keratinocytes/metabolism | 2 | 1.0 |
Alleles | 8 | 0.0 |
DNA Methylation | 2 | 0.0 |
Genes, Tumor Suppressor/*genetics | 3 | 0.0 |
Muscle Proteins/genetics | 2 | 2.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Protein p16/genetics | 2 | 2.0 |
Genes, myc/*physiology | 7 | 50.0 |
*Chromosome Deletion | 2 | 0.0 |
Prostatic Neoplasms/*genetics | 3 | 1.0 |
Apoptosis/*genetics/physiology | 2 | 10.0 |
Proto-Oncogene Proteins c-myc/physiology | 2 | 14.0 |
Protein p53/*genetics | 2 | 1.0 |
Gene Expression Profiling | 5 | 0.0 |
*Cytogenetics | 2 | 66.0 |
*Chromosome Mapping | 4 | 0.0 |
DNA | 2 | 0.0 |
Exons | 13 | 0.0 |
Protein Biosynthesis | 8 | 0.0 |
Proto-Oncogene Proteins c-fos/analysis | 2 | 16.0 |
Proto-Oncogene Proteins c-jun/analysis | 2 | 22.0 |
Proto-Oncogene Proteins c-myc/analysis | 2 | 11.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Bone Marrow/pathology | 2 | 0.0 |
Adenoviridae/genetics | 3 | 0.0 |
Gene Library | 2 | 0.0 |
Zinc Fingers | 2 | 0.0 |
DNA/genetics | 7 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Cyclin D1 | 2 | 1.0 |
Rats, Inbred F344 | 4 | 1.0 |
Retinoblastoma Protein/physiology | 2 | 5.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Nuclear Proteins/*physiology | 2 | 1.0 |
Saccharomyces cerevisiae/genetics | 4 | 0.0 |
Exons/*genetics | 2 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Epidermal Growth Factor/*pharmacology | 2 | 0.0 |
Mitogens/pharmacology | 2 | 0.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Cell Transformation, Viral | 4 | 1.0 |
Coturnix | 2 | 8.0 |
Oncogene Protein p55(v-myc)/*metabolism | 2 | 100.0 |
RNA, Neoplasm/genetics | 5 | 1.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
RNA, Messenger | 2 | 0.0 |
*Genes, ras | 6 | 2.0 |
RNA, Neoplasm/genetics/metabolism | 4 | 2.0 |
Radiation Tolerance/*genetics | 2 | 3.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Fungal Proteins/*genetics | 2 | 1.0 |
Age Factors | 3 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Chromosomes, Human, Pair 14 | 5 | 3.0 |
Chromosomes, Human, Pair 18 | 5 | 4.0 |
Lymphoma, B-Cell/*genetics/immunology | 2 | 22.0 |
Proto-Oncogene Proteins c-bcl-2 | 5 | 3.0 |
Proto-Oncogenes/*genetics | 3 | 4.0 |
Gene Expression/drug effects | 4 | 0.0 |
Mice, Inbred Strains | 3 | 0.0 |
Gene Rearrangement | 8 | 1.0 |
Lung Neoplasms/drug therapy/*metabolism/*pathology | 2 | 100.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Epitopes/analysis | 2 | 0.0 |
Escherichia coli | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 3 | 1.0 |
*Genes, Structural | 2 | 0.0 |
Oncogene Proteins, Fusion/genetics | 2 | 2.0 |
*Restriction Mapping | 3 | 8.0 |
Enzyme Induction | 3 | 0.0 |
Lymph Nodes/chemistry | 2 | 8.0 |
Chickens | 5 | 0.0 |
*Genes, jun | 2 | 4.0 |
Chromosomes, Human, Pair 2 | 3 | 1.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
Fatal Outcome | 2 | 0.0 |
*Gene Deletion | 3 | 0.0 |
*Chromosomes, Human, Pair 17 | 3 | 0.0 |
*Chromosomes, Human, Pair 5 | 2 | 0.0 |
Leukemia, Promyelocytic, Acute/*genetics | 3 | 7.0 |
Breast Neoplasms/etiology/*genetics | 2 | 6.0 |
Chromosomes, Human | 2 | 3.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Genes, erbB-1 | 2 | 11.0 |
Actins/genetics | 4 | 3.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
*Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 9.0 |
Immunoglobulin A/genetics | 2 | 20.0 |
Immunoglobulin G/genetics | 2 | 5.0 |
*Genes, Immunoglobulin | 5 | 2.0 |
Mice, Inbred C57BL | 4 | 0.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Carcinoma, Small Cell/*genetics | 2 | 3.0 |
Lung Neoplasms/*genetics | 4 | 1.0 |
Ovarian Neoplasms/*genetics | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Cell Count | 2 | 0.0 |
DNA Probes/genetics | 2 | 1.0 |
Gene Amplification/genetics | 2 | 3.0 |
Cell Cycle/physiology | 2 | 0.0 |
Retinoblastoma Protein/*physiology | 2 | 6.0 |
Tumor Markers, Biological/*genetics | 3 | 2.0 |
DNA Replication | 2 | 0.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 2 | 1.0 |
Codon | 6 | 1.0 |
Genes, fos | 3 | 2.0 |
Genes, jun | 2 | 2.0 |
*Signal Transduction | 4 | 0.0 |
DNA/physiology | 2 | 20.0 |
Biotin | 3 | 4.0 |
Cell Survival | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Cell Cycle/genetics | 3 | 2.0 |
Lymphocyte Activation | 2 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Breast Neoplasms/chemistry | 2 | 11.0 |
Proto-Oncogene Proteins/*analysis | 2 | 1.0 |
Glioma/*genetics | 3 | 3.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
Cytoplasm/ultrastructure | 2 | 3.0 |
RNA Splicing | 2 | 0.0 |
Lymphoma/genetics/pathology | 2 | 40.0 |
DNA Damage/*physiology | 2 | 4.0 |
Substrate Specificity | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 2 | 1.0 |
*Introns | 2 | 0.0 |
*Chromosomes, Human, Pair 14 | 3 | 1.0 |
*Chromosomes, Human, Pair 8 | 5 | 2.0 |
*Gene Rearrangement | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
MyoD Protein | 2 | 22.0 |
*Mutagenesis, Site-Directed | 2 | 2.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Carcinoma/*genetics | 2 | 1.0 |
Stomach Neoplasms/*genetics | 2 | 1.0 |
Protein p53/genetics/*metabolism | 2 | 1.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Adenovirus E1A Proteins/metabolism | 2 | 6.0 |
Casein Kinases | 2 | 4.0 |
Proto-Oncogene Proteins c-myc/*genetics/*metabolism | 2 | 100.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
*Cysteine | 2 | 5.0 |
Oligonucleotide Probes | 4 | 0.0 |
Platelet-Derived Growth Factor/physiology | 2 | 5.0 |
Pregnancy | 7 | 0.0 |
Nucleic Acid Conformation | 2 | 0.0 |
RNA, Messenger/genetics/isolation & purification | 2 | 3.0 |
Protein p53/biosynthesis | 2 | 1.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Neoplasms, Experimental/genetics | 2 | 15.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Genes, ras/genetics | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
DNA Probes | 5 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
DNA/analysis | 4 | 0.0 |
Lymphoma/*genetics/pathology | 2 | 15.0 |
Species Specificity | 6 | 0.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Apoptosis/genetics | 2 | 0.0 |
Cluster Analysis | 2 | 1.0 |
*Carcinogens | 2 | 6.0 |
Crosses, Genetic | 2 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Placenta/*physiology | 2 | 7.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
Muscle Proteins/*genetics | 2 | 1.0 |
Myogenin | 2 | 14.0 |
Proto-Oncogene Proteins c-fos | 2 | 3.0 |
*Exons | 3 | 0.0 |
Medulloblastoma/*genetics | 2 | 9.0 |
Proto-Oncogene Proteins c-myc | 13 | 34.0 |
DNA/*metabolism | 2 | 0.0 |
Lymphoma/*genetics/immunology | 2 | 50.0 |
Trisomy | 2 | 1.0 |
Oncogene Protein p55(v-myc) | 2 | 100.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Receptors, Antigen, T-Cell/*genetics | 2 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta | 2 | 5.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Retroviridae/genetics | 3 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
Leukemia, Myelocytic, Acute | 2 | 7.0 |
DNA Restriction Enzymes | 7 | 1.0 |
*Genes, Viral | 3 | 1.0 |
Burkitt Lymphoma/genetics | 3 | 33.0 |
Leukemia, Lymphocytic/genetics | 2 | 18.0 |
Chickens/genetics | 2 | 4.0 |
Leukemia/*genetics | 3 | 2.0 |
Chromosome Breakage | 2 | 2.0 |
*Cloning, Molecular | 2 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Plasmacytoma/*genetics | 2 | 40.0 |
Acetyltransferases/*metabolism | 2 | 2.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
